Product Information

Sequence: H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Appearance: White Powder

Purity (HPLC): ≥99.0%

Single Impurity (HPLC): ≤1.0%

Sodium Content (HPLC): 5.0%-12.0%

Moisture Content (Karl Fischer): ≤10.0%

Peptide Content: ≥80.0%

Storage: Store at 2-8 degrees Celsius in a dry and cool place.

Core Features

1. 1. Innovative Mechanism of Action
   Retatrutide is the first triple agonist peptide targeting GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor). By synergistically regulating appetite, glucose homeostasis, and energy metabolism, it achieves highly effective weight loss and metabolic improvement.

   • Human Receptor EC₅₀ Values: GIPR (0.0643 nM) > GLP-1R (0.775 nM) > GCGR (5.79 nM), demonstrating potent activity.

   • 
     

2. 2. Outstanding Clinical Weight Loss Efficacy

   • 24.2% Average Weight Loss at 48 Weeks: In Phase II clinical trials, the 12mg dose group (338 obese patients) achieved 100% of subjects with ≥5% weight loss, 83% with ≥15% weight loss, significantly outperforming the placebo group (2%).

   • Rapid Onset: 17.5% weight reduction at 24 weeks, with efficacy showing dose dependence.

   • 
     

3. 3. Potential for Multiple Indications

   • Obesity Treatment: Phase III head-to-head trial (TRIUMPH-5) underway, comparing with Tirzepatide.

   • Type 2 Diabetes: Reduced HbA1c by 2.02% (12mg group) at 36 weeks, superior to Dulaglutide (1.41%).

   • Non-Alcoholic Steatohepatitis (NASH): 90% of patients restored normal liver fat content after 48 weeks.

Company Introduction

Introduction to transportation

Product Certificates